poorly differentiated chordoma
poorly differentiated chordoma
Explore linked clinical trials. Standard reference: MONDO:09581641 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, atypical teratoid rhabdoid tumor, chordoma, kidney medullary carcinoma, mixed neoplasm, neoplasm, poorly differentiated chordoma, rhabdoid tumor, sarcoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT05286801 |